Results 221 to 230 of about 14,107 (263)
Some of the next articles are maybe not open access.
Amyloid, 1994
The major component of Alzheimer's disease amyloid is the 4 kDa peptide βA4 which is produced from an integral membrane protein (amyloid beta precursor protein, AβPP) by proteolytic processing. Cleavage of the βA4 domain from the precursor protein is part of a complex process which results in the release of AβPP from the membrane.
Genevieve Evin +2 more
openaire +3 more sources
The major component of Alzheimer's disease amyloid is the 4 kDa peptide βA4 which is produced from an integral membrane protein (amyloid beta precursor protein, AβPP) by proteolytic processing. Cleavage of the βA4 domain from the precursor protein is part of a complex process which results in the release of AβPP from the membrane.
Genevieve Evin +2 more
openaire +3 more sources
Amyloid, 1998
Proteolytic cleavage of the amyloid precursor protein (A beta PP) results in the generation of the amyloidogenic fragment known as amyloid beta peptide (A beta). Deposition of A beta in the brain parenchyma and cerebrovasculature is a feature of Alzheimer's disease (AD). To date, the process whereby A beta is generated and deposited remains unclear. We
E R, Simons +11 more
openaire +4 more sources
Proteolytic cleavage of the amyloid precursor protein (A beta PP) results in the generation of the amyloidogenic fragment known as amyloid beta peptide (A beta). Deposition of A beta in the brain parenchyma and cerebrovasculature is a feature of Alzheimer's disease (AD). To date, the process whereby A beta is generated and deposited remains unclear. We
E R, Simons +11 more
openaire +4 more sources
Successive cleavage of β-amyloid precursor protein by γ-secretase
Seminars in Cell & Developmental Biology, 2020γ-Secretase is a multimeric aspartyl protease that cleaves the membrane-spanning region of the β-carboxyl terminal fragment (βCTF) generated from β-amyloid precursor protein. γ-Secretase defines the generated molecular species of amyloid β-protein (Aβ), a critical molecule in the pathogenesis of Alzheimer's disease (AD).
Satoru, Funamoto +3 more
openaire +2 more sources
ADAMs family members as amyloid precursor protein α‐secretases
Journal of Neuroscience Research, 2003AbstractIn the non‐amyloidogenic pathway, the Alzheimer's amyloid precursor protein (APP) is cleaved within the amyloid‐β domain by α‐secretase precluding deposition of intact amyloid‐β peptide. The large ectodomain released from the cell surface by the action of α‐secretase has several neuroprotective properties.
Allinson, Tobias M. J. +3 more
openaire +2 more sources
Iron Levels Modulate α‐Secretase Cleavage of Amyloid Precursor Protein
Journal of Neurochemistry, 1995Abstract: The amyloid precursor protein (APP) is a membrane‐spanning glycoprotein that is the source of βA4 peptides, which aggregate in Alzheimer's disease to form senile plaques. APP is cleaved within the βA4 sequence to release a soluble N‐terminal derivative (APPsol), which has a wide range of trophic and protective functions.
S, Bodovitz +3 more
openaire +2 more sources
β-Secretase Processing of the Alzheimer's Amyloid Protein Precursor (APP)
Journal of Molecular Neuroscience, 2003An integral membrane aspartyl protease, BACE, is responsible for beta-secretase processing of the beta-amyloid precursor protein (APP) to the large secreted sAPPbeta and membrane-bound CTFbeta of 99 residues. CTFbeta is subsequently cleaved within the membrane by gamma-secretase to the amyloid beta protein (Abeta) that is deposited in the Alzheimer's ...
Laura, Marlow +3 more
openaire +2 more sources
Recognition of the amyloid precursor protein by human γ-secretase
Science, 2019The machinery behind amyloid peptides β-Amyloid peptides, which are derived from amyloid precursor protein (APP), form the plaques in the brain that are characteristic of Alzheimer's disease. Zhou et al.
Rui Zhou +5 more
openaire +2 more sources
Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers
Trends in Molecular Medicine, 2014Recently revised diagnostic guidelines for Alzheimer's disease (AD) emphasise the use of biomarkers, heralding a paradigm shift towards a more biological definition of the disorder. Currently available biomarkers offer added diagnostic accuracy in certain situations, but their performance in terms of early diagnostic sensitivity and specificity does ...
Robert, Perneczky +2 more
openaire +2 more sources
Targeting amyloid precursor protein secretases: Alzheimer's disease and beyond
Drug News & Perspectives, 2010This review evaluates past and present clinical trials, as well as the current preclinical drug candidates focused on treating Alzheimer's disease (AD), in order to better assess the trends in AD drug discovery in context with specific drug mechanisms.
openaire +2 more sources
ChemInform, 2004
AbstractFor Abstract see ChemInform Abstract in Full Text.
Gerald Koelsch +4 more
openaire +1 more source
AbstractFor Abstract see ChemInform Abstract in Full Text.
Gerald Koelsch +4 more
openaire +1 more source

